Morgan Stanley Stock Ahead of Q3 Earnings: Buy, Hold or Sell?

Morgan Stanley’s Q3 2026 consensus calls for revenue of $19.63 billion, up 7.7% year over year, and EPS of $2.83, up 1.1%; the EPS estimate was cut 4.7% over the past seven days, and the model does not predict a beat. Stronger equity trading and net interest revenue are expected to be offset by muted investment-banking activity, weaker underwriting and elevated expenses; the stock trades at 14.45x forward earnings versus 12.61x for its industry. The article recommends waiting for results before initiating positions, while noting $10 trillion in combined wealth and asset management client assets, a 15% dividend increase to $1.15 per share, and a reauthorized $20 billion buyback.

Analysis

The key risk is not simply whether Morgan Stanley beats a low earnings bar; it is whether any trading-driven upside converts to earnings after compensation and technology costs. A headline revenue beat led by equities could be sold if expense growth absorbs the incremental revenue or underwriting remains soft. Conversely, stable wealth-management NII and controlled expenses would make the diversified franchise more valuable than the cautious near-term setup implies.

For the next few sessions, JPMorgan and Goldman Sachs results on Oct. 13 may reset expectations for the sector before Morgan Stanley reports Oct. 14. In the 1–3 month window, expense trajectory, wealth NII and evidence that deal pipelines are converting—not just IPO proceeds—matter more than one quarter’s trading volatility. Over 6–18 months, wealth and asset-management scale and the MUFG alliance could support earnings resilience, but the article provides no evidence yet that these are accelerating incremental profits.

Contrarian point: the recent estimate cuts and lack of a modeled beat may already limit the penalty for a merely in-line quarter, while a premium valuation leaves less room for an expense or guidance miss. Still, the relative valuation alone does not establish that JPM or Goldman is a better business or a reliable hedge. Treat stated estimates and company outlook as forecasts to verify against reported results.

Key Decisions for Investors

• Avoid adding outright MS exposure before the Oct. 14 release; use JPM and GS results on Oct. 13 as an initial read-through, not a substitute for Morgan Stanley’s own expense and wealth-management disclosures.
• For a short-horizon relative-value expression, consider a small, risk-limited short MS / long JPM position only if MS rallies into earnings without improving estimate revisions. The thesis is valuation and execution asymmetry, not a claim that JPM has superior long-term fundamentals; cap event risk because the businesses and earnings drivers differ.
• After the print, favor MS if wealth-management NII is firm and expense growth is controlled despite trading variability. Reduce or avoid exposure if costs outpace revenue or management signals weaker capital-markets conversion; those would undermine the case for paying a premium multiple.
• Falsifiers: a sustained decline in MS’s relative performance versus JPM after earnings would challenge the relative short; better-than-expected expense discipline and improved deal-pipeline commentary would invalidate the cautious MS thesis. Verify reported segment revenues, compensation/expense trends, wealth NII, and guidance before acting.